1014 ET - The danuglipron setback has pushed Pfizer to the sidelines in the booming obesity market, but Viking Therapeutics' VK2735 could get the drugmaker back in the game, say analysts at William Blair. In a note, Andy Hsieh and Alexandra Ramsey say VK2735, in development as a pill and as an injection, could offer Pfizer a rare opportunity to reestablish not only a mere presence in obesity, but also a leading position beyond the current Novo Nordisk/Eli Lilly duopoly. With shares down significantly over the past six months, Viking sports a market cap of around $2.5 billion, but William Blair sees a fair value of $9.2 billion, or about $82 a share. Viking surges 9.7% to $24.43. (colin.kellaher@wsj.com)

(END) Dow Jones Newswires

April 14, 2025 10:14 ET (14:14 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.